Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

NCT00206167 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00206167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00206167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
September 30, 2007
Enrollment
1,600
Sites
216

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease